Health
Biotech funding and drug-price deals lead STAT’s morning briefing
STAT’s The Readout newsletter highlighted ARPA-H funding for companies developing custom RNA therapies and examined new drug-price agreements.
STAT’s The Readout newsletter highlighted ARPA-H funding for biotechnology companies developing custom RNA therapies. The roundup also said President Trump presented new agreements with biopharmaceutical companies as part of his effort to reduce drug costs.
STAT’s John Wilkerson reported that the agreements might have limited effect and could conflict with the administration’s own objectives. The newsletter also reported that a company had submitted applications to the FDA and the UK’s MHRA seeking marketing approval for AMT-130, a treatment for Huntington’s disease.
— 30 —
RawNews Desk
— RawNews Desk is the staff byline of RawNews. Articles published under it are written with AI assistance from a single named source report by an approved publication, checked by automated validation against that source before publication, and always name and link the original publisher. See our Editorial Standards page for how this works and our Corrections page for how to report an error.
